Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML
Jian-Ying Zhou
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorSong Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorHai-Long Yuan
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Search for more papers by this authorYa-Jing Xu
Department of Hematology, Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorXiao-Bing Huang
Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Search for more papers by this authorSu-Jun Gao
Hematology Section, Cancer Center, The First Hospital of Jilin University, Changchun, China
Search for more papers by this authorYi-Cheng Zhang
Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Search for more papers by this authorFang Zhou
Hematology Department, The 960th Hospital of The People's Liberation Army (PLA) Joint Logistics Support Force, Jinan, China
Search for more papers by this authorYue Liu
Hematology Department, The 960th Hospital of The People's Liberation Army (PLA) Joint Logistics Support Force, Jinan, China
Search for more papers by this authorXian-Min Song
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorYu Cai
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorXiao-Liang Liu
Hematology Section, Cancer Center, The First Hospital of Jilin University, Changchun, China
Search for more papers by this authorYi Luo
Department of Hematology, Bone Marrow Transplant Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Search for more papers by this authorLu-Xin Yang
Department of Hematology, Bone Marrow Transplant Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Search for more papers by this authorJian-Min Yang
Department of Hematology, Changhai Hospital, The Naval Medical University, Shanghai, China
Search for more papers by this authorLi-Bing Wang
Department of Hematology, Changhai Hospital, The Naval Medical University, Shanghai, China
Search for more papers by this authorYu-Hua Li
Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Search for more papers by this authorRui Huang
Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Search for more papers by this authorShun-Qing Wang
Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
Search for more papers by this authorMing Zhou
Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
Search for more papers by this authorYu-Jun Dong
Department of Hematology, Peking University First Hospital, Beijing, China
Search for more papers by this authorQian Wang
Department of Hematology, Peking University First Hospital, Beijing, China
Search for more papers by this authorXi Zhang
Xinqiao Hospital, The Third Military Medical University, Chongqing, China
Search for more papers by this authorYi-Mei Feng
Xinqiao Hospital, The Third Military Medical University, Chongqing, China
Search for more papers by this authorXin Du
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for more papers by this authorWei Ling
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for more papers by this authorHan Zhu
Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China
Search for more papers by this authorZun-Min Zhu
Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China
Search for more papers by this authorXiang-Li Chen
Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China
Search for more papers by this authorShi-Yu Wang
Department of Hematology, Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorFan-Kai Meng
Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Search for more papers by this authorKe-Hong Bi
Department of Hematology, School of First Affiliated Hospital of Shandong First Medical University, Shandong Province Qianfoshan Hospital, Jinan, China
Search for more papers by this authorNing Huang
Department of Hematology, School of First Affiliated Hospital of Shandong First Medical University, Shandong Province Qianfoshan Hospital, Jinan, China
Search for more papers by this authorMing Jiang
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Search for more papers by this authorTing Niu
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
Search for more papers by this authorJie Ji
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
Search for more papers by this authorDing-Ming Wan
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorZhi-Lei Bian
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorYi Chen
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorLi Liu
Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an, China
Search for more papers by this authorXue-Qian Yan
Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an, China
Search for more papers by this authorXi Yang
Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Search for more papers by this authorHai Yi
Department of Hematology, Western Theater General Hospital of the People's Liberation Army of China, Chengdu, China
Search for more papers by this authorXu-Dong Wei
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Search for more papers by this authorXin Li
Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorQian Cheng
Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorCheng-Lu Yuan
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
Search for more papers by this authorWen Wang
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
Search for more papers by this authorYu-Hong Zhou
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
Search for more papers by this authorBao-Dong Ye
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
Search for more papers by this authorJing Ding
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYe-Jun Wu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorQiu-Sha Huang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Lu Zhu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYu-Hong Chen
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYun He
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorFeng-Rong Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYuan-Yuan Zhang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Dong Mo
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorWei Han
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorJing-Zhi Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYu Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorHuan Chen
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiang-Yu Zhao
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYing-Jun Chang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorKai-Yan Liu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Jun Huang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorCorresponding Author
Xiao-Hui Zhang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Correspondence
Xiao-Hui Zhang, No. 11 Xizhimen South St, Xicheng District, Beijing 100044, China.
Email: zhangxh@bjmu.edu.cn
Search for more papers by this authorJian-Ying Zhou
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorSong Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorHai-Long Yuan
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Search for more papers by this authorYa-Jing Xu
Department of Hematology, Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorXiao-Bing Huang
Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Search for more papers by this authorSu-Jun Gao
Hematology Section, Cancer Center, The First Hospital of Jilin University, Changchun, China
Search for more papers by this authorYi-Cheng Zhang
Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Search for more papers by this authorFang Zhou
Hematology Department, The 960th Hospital of The People's Liberation Army (PLA) Joint Logistics Support Force, Jinan, China
Search for more papers by this authorYue Liu
Hematology Department, The 960th Hospital of The People's Liberation Army (PLA) Joint Logistics Support Force, Jinan, China
Search for more papers by this authorXian-Min Song
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorYu Cai
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorXiao-Liang Liu
Hematology Section, Cancer Center, The First Hospital of Jilin University, Changchun, China
Search for more papers by this authorYi Luo
Department of Hematology, Bone Marrow Transplant Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Search for more papers by this authorLu-Xin Yang
Department of Hematology, Bone Marrow Transplant Center, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Search for more papers by this authorJian-Min Yang
Department of Hematology, Changhai Hospital, The Naval Medical University, Shanghai, China
Search for more papers by this authorLi-Bing Wang
Department of Hematology, Changhai Hospital, The Naval Medical University, Shanghai, China
Search for more papers by this authorYu-Hua Li
Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Search for more papers by this authorRui Huang
Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
Search for more papers by this authorShun-Qing Wang
Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
Search for more papers by this authorMing Zhou
Department of Hematology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China
Search for more papers by this authorYu-Jun Dong
Department of Hematology, Peking University First Hospital, Beijing, China
Search for more papers by this authorQian Wang
Department of Hematology, Peking University First Hospital, Beijing, China
Search for more papers by this authorXi Zhang
Xinqiao Hospital, The Third Military Medical University, Chongqing, China
Search for more papers by this authorYi-Mei Feng
Xinqiao Hospital, The Third Military Medical University, Chongqing, China
Search for more papers by this authorXin Du
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for more papers by this authorWei Ling
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
Search for more papers by this authorHan Zhu
Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China
Search for more papers by this authorZun-Min Zhu
Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China
Search for more papers by this authorXiang-Li Chen
Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China
Search for more papers by this authorShi-Yu Wang
Department of Hematology, Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorFan-Kai Meng
Department of Hematology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
Search for more papers by this authorKe-Hong Bi
Department of Hematology, School of First Affiliated Hospital of Shandong First Medical University, Shandong Province Qianfoshan Hospital, Jinan, China
Search for more papers by this authorNing Huang
Department of Hematology, School of First Affiliated Hospital of Shandong First Medical University, Shandong Province Qianfoshan Hospital, Jinan, China
Search for more papers by this authorMing Jiang
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Search for more papers by this authorTing Niu
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
Search for more papers by this authorJie Ji
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
Search for more papers by this authorDing-Ming Wan
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorZhi-Lei Bian
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Search for more papers by this authorYi Chen
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorLi Liu
Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an, China
Search for more papers by this authorXue-Qian Yan
Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an, China
Search for more papers by this authorXi Yang
Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
Search for more papers by this authorHai Yi
Department of Hematology, Western Theater General Hospital of the People's Liberation Army of China, Chengdu, China
Search for more papers by this authorXu-Dong Wei
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Search for more papers by this authorXin Li
Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorQian Cheng
Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China
Search for more papers by this authorCheng-Lu Yuan
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
Search for more papers by this authorWen Wang
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
Search for more papers by this authorYu-Hong Zhou
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
Search for more papers by this authorBao-Dong Ye
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
Search for more papers by this authorJing Ding
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYe-Jun Wu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorQiu-Sha Huang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Lu Zhu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYu-Hong Chen
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYun He
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorFeng-Rong Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYuan-Yuan Zhang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Dong Mo
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorWei Han
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorJing-Zhi Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYu Wang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorHuan Chen
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiang-Yu Zhao
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorYing-Jun Chang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorKai-Yan Liu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorXiao-Jun Huang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Search for more papers by this authorCorresponding Author
Xiao-Hui Zhang
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
Correspondence
Xiao-Hui Zhang, No. 11 Xizhimen South St, Xicheng District, Beijing 100044, China.
Email: zhangxh@bjmu.edu.cn
Search for more papers by this authorJian-Ying Zhou and Song Wang contributed equally to this work.
Abstract
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curable treatment. The outcomes after transplant are influenced by both disease characteristics and patient comorbidities. To develop a novel prognostic model to predict the post-transplant survival of CMML patients, we identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499), anemia (HR 3.439), bone marrow blast cell count (HR 2.095), and no chronic graft versus host disease (cGVHD; HR 4.799) were independently associated with worse survival. A novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anemia, cGVHD) was developed and the points were assigned according to the regression equation. The patients were categorized into low risk (0–1), intermediate risk (2, 3), and high risk (4–6) three groups and the 3-year overall survival (OS) were 93.3% (95%CI, 61%–99%), 78.9% (95%CI, 60%–90%), and 51.6% (95%CI, 32%–68%; p < .001), respectively. In internal and external validation cohort, the area under the receiver operating characteristic (ROC) curves of the ABLAG model were 0.829 (95% CI, 0.776–0.902) and 0.749 (95% CI, 0.684–0.854). Compared with existing models designed for the nontransplant setting, calibration plots, and decision curve analysis showed that the ABLAG model revealed a high consistency between predicted and observed outcomes and patients could benefit from this model. In conclusion, combining disease and patient characteristic, the ABLAG model provides better survival stratification for CMML patients receiving allo-HSCT.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author, Xiao-Hui Zhang, PhD, MD. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
Supporting Information
| Filename | Description |
|---|---|
| ajh26999-sup-0001-Supinfo.docxWord 2007 document , 42.6 KB | Data S1: Supporting information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36(7): 1703-1719.
- 2Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391-2405.
- 3Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017; 130(2): 126-136.
- 4Chan O, Renneville A, Padron E. Chronic myelomonocytic leukemia diagnosis and management. Leukemia. 2021; 35(6): 1552-1562.
- 5Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011; 96(3): 375-383.
- 6Nie Y, Shao L, Zhang H, et al. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients. Exp Hematol Oncol. 2022; 11(1): 32.
- 7Itzykson R, Fenaux P, Bowen D, et al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018; 2(6):e150.
- 8Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019; 94(7): 767-779.
- 9Zheng X, Lv L, Li X, Jiang E. Efficacy and safety of hypomethylating agents in chronic myelomonocytic leukemia: a single-arm meta-analysis. Glob Med Genet. 2022; 9(2): 141-151.
- 10Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016; 7:10767.
- 11Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005; 11(9): 713-720.
- 12Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011; 17(6): 908-915.
- 13Park S, Labopin M, Yakoub-Agha I, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013; 90(5): 355-364.
- 14Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the chronic malignancies working Party of the European Group for blood and marrow transplantation. Br J Haematol. 2015; 171(2): 239-246.
- 15Kongtim P, Popat U, Jimenez A, et al. Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2016; 22(1): 47-53.
- 16Itonaga H, Aoki K, Aoki J, et al. Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a Nationwide retrospective analysis in Japan. Biol Blood Marrow Transplant. 2018; 24(4): 840-848.
- 17Woo J, Choi DR, Storer BE, et al. Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 2020; 105(3): 652-660.
- 18de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017; 129(13): 1753-1762.
- 19Robin M, de Wreede LC, Padron E, et al. Role of allogeneic transplantation In chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022; 140: 1408-1418.
- 20Sharma P, Shinde SS, Damlaj M, et al. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk Lymphoma. 2017; 58(4): 872-881.
- 21Onida F. Models of prognostication in chronic myelomonocytic leukemia. Curr Hematol Malig Rep. 2017; 12(6): 513-521.
- 22Motohashi K, Fujisawa S, Doki N, et al. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. Leuk Lymphoma. 2018; 59(6): 1332-1337.
- 23Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013; 121(15): 3005-3015.
- 24Wedge E, Hansen JW, Dybedal I, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021; 27(12): 991.e991-991.e999.
10.1016/j.jtct.2021.08.028 Google Scholar
- 25Mei M, Pillai R, Kim S, et al. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2022; 108: 150-160.
10.3324/haematol.2021.280203 Google Scholar
- 26Zang DY, Deeg HJ, Gooley T, et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol. 2000; 110(1): 217-222.
- 27Itonaga H, Iwanaga M, Aoki K, et al. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide retrospective study. Leuk Res. 2016; 41: 48-55.
- 28Liu HD, Ahn KW, Hu ZH, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2017; 23(5): 767-775.
- 29Gagelmann N, Badbaran A, Beelen DW, et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021; 5(6): 1760-1769.
- 30Kröger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic leukaemia working party of the European Group for blood and marrow transplantation (EBMT). Br J Haematol. 2002; 118(1): 67-73.
- 31Mo XD, Xu LP, Zhang XH, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant. 2015; 50(1): 127-133.
- 32Yeshurun M, Weisdorf D, Rowe JM, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019; 3(4): 670-680.
- 33Kim DY, Lee JH, Lee JH, et al. Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD. Bone Marrow Transplant. 2010; 45(7): 1174-1180.
- 34Lazaryan A, Arora M. Evolving concepts in prognostic scoring of chronic GvHD. Bone Marrow Transplant. 2017; 52(10): 1361-1366.
- 35Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(3): 352-372.
- 36Robin M, Fenaux P. Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia? Biol Blood Marrow Transplant. 2016; 22(1): 1-2.
- 37Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-francophone des Myelodysplasies. J Clin Oncol. 2012; 30(36): 4533-4540.
- 38Potter VT, Iacobelli S, van Biezen A, et al. Comparison of intensive chemotherapy and hypomethylating agents before allogeneic stem cell transplantation for advanced myelodysplastic syndromes: a study of the myelodysplastic syndrome subcommittee of the chronic malignancies working party of the European society for blood and marrow transplant research. Biol Blood Marrow Transplant. 2016; 22(9): 1615-1620.
- 39Elena C, Galli A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128(10): 1408-1417.
- 40Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014; 28(11): 2206-2212.
- 41Han W, Zhou F, Wang Z, et al. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance. Int J Hematol. 2022; 115(1): 21-32.
- 42Kim HY, Lee KO, Park S, et al. Poor prognostic implication of ASXL1 mutations in Korean patients with chronic myelomonocytic leukemia. Ann Lab Med. 2018; 38(6): 495-502.
- 43Cui Y, Tong H, Du X, et al. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. Exp Hematol Oncol. 2015; 4: 14.
- 44Gagelmann N, Badbaran A, Bogdanov R, et al. Clinical relevance of somatic mutations in chronic myelomonocytic leukemia undergoing allogeneic stem cell transplantation. Blood. 2019; 134(Supplement_1) 1713-1713: 1713.
10.1182/blood-2019-121969 Google Scholar
- 45Aguirre LE, Ali NA, Sallman DA, et al. Outcome predictors and timing considerations for allogeneic stem cell transplantation in chronic myelomonocytic leukemia. Clin Lymphoma Myeloma Leukemia. 2022; 22: S320.
- 46Patnaik MM, Wassie EA, Padron E, et al. Chronic myelomonocytic leukemia in young patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood. 2014; 124(21): 4633.
- 47Kröger N, Schroeder T, Zabelina T, et al. Post-allogeneic monitoring with molecular markers detected by pre-transplant next generation sequencing (NGS) predicts clinical relapse in patients with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120(21): 4212.
- 48Rautenberg C, Betz B, Wieczorek D, et al. Quantitative next-generation sequencing (NGS) based monitoring of minimal residual disease (MRD) predicts imminent relapse in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation. Blood. 2017; 130:2005.
- 49Wang L, Chen R, Li L, Zhu L, Huang X, Ye X. Prognostic implication of early minimal residual disease evaluation in patients with chronic myelomonocytic leukemia. Am J Cancer Res. 2022; 12(5): 2216-2225.
- 50Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45-52.
- 51Gagelmann N, Bogdanov R, Stolzel F, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Transplant Cell Ther. 2021; 27(1): 95.e91-95.e94.
10.1016/j.bbmt.2020.10.007 Google Scholar
- 52Ades L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013; 37(6): 609-613.
- 53Patnaik MM, Wassie EA, Padron E, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015; 5:e270.
- 54Pophali P, Matin A, Mangaonkar AA, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020; 10(11): 121.
- 55Onida F, Sbianchi G, Radujkovic A, et al. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. Bone Marrow Transplant. 2022; 57(6): 896-902.
- 56Xu Y, Guo R, Miao M, Zhang G, Lan J, Jin J. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study. Invest New Drugs. 2022; 40(5): 1117-1124.
- 57Gross SA, Irons RD, Scott PK, et al. A case-control study of chronic myelomonocytic leukemia (CMML) in Shanghai, China: evaluation of risk factors for CMML, with special focus on benzene. Arch Environ Occup Health. 2012; 67(4): 206-218.
- 58Chen B, Ma Y, Xu X, et al. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China. Leuk Res. 2010; 34(4): 458-462.
- 59Ma L, Jiang L, Yang W, et al. Real-world data of chronic myelomonocytic leukemia: a chinese single-center retrospective study. Cancer Med. 2021; 10(5): 1715-1725.
- 60Pan X, Gao M, Sun Y, et al. Significance of WT1 and multiparameter flow cytometry assessment in patients with chronic myelomonocytic leukemia receiving allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol. 2022; 44(3): 510-517.
- 61Wang T, Li W-Y, Qi X-F, et al. Clinical analysis on treatment of chronic myelomonocytic leukemia with allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015; 23(6): 1667-1672.
- 62Chao S, Sujiang Z, Chun Q, Xiangchou Y, Jianyong L. Clinical manifestation of the SRSF2 gene mutation in Chinese patients with chronic myelomonocytic leukemia. Chin Med J (Engl). 2014; 127(24): 4215-4219.
- 63Cui Y, Tong H, Du X, et al. TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. Stem Cell Investig. 2016; 3: 50.
- 64Jentzsch M, Dohring C, Linke R, et al. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Am J Hematol. 2019; 94(12): 1344-1352.
- 65D'Souza A, Fretham C, Lee SJ, et al. Corrigendum to ‘Current use and trends in hematopoietic cell transplantation in the United States’ [transplantation and cellular therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022; 28(10): 715-716.
- 66D'Souza A, Fretham C, Lee SJ, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26(8): e177-e182.
- 67Sophie S, Yves B, Frederic B. Current status and perspectives of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia. Stem Cells Transl Med. 2022; 11(5): 461-477.
- 68Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018; 53(5): 565-575.
- 69Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015; 350:g7594.
